-+ 0.00%
-+ 0.00%
-+ 0.00%

Definium Q1 FY26 net loss widens to $77.1 million; R&D expense jumps 77.5% to $41.5 million

PUBT·05/07/2026 20:02:33
Listen to the news
Definium Q1 FY26 net loss widens to $77.1 million; R&D expense jumps 77.5% to $41.5 million
  • Definium Therapeutics posted a net loss of USD 77.1 million, widening from USD 23.3 million a year earlier; loss per share deepened to USD 0.71 from USD 0.27.
  • Operating loss widened to USD 59.2 million from USD 32.2 million as R&D expenses climbed to USD 41.5 million from USD 23.4 million.
  • Cash, cash equivalents, and investments fell to USD 373.4 million from USD 411.6 million at Dec. 31, 2025; cash runway expected to extend into 2028.
  • Enrollment completed for Phase 3 Emerge in MDD and Phase 3 Voyage in GAD, with topline data expected in late 2Q 2026 and early 3Q 2026.
  • Panorama GAD target enrollment updated to 200 with screening closed, pushing topline data to late 3Q 2026; Phase 3 PTSD study Haven planned for 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260507422734) on May 07, 2026, and is solely responsible for the information contained therein.